N.Y. postpones opioid bellwether trial as novel coronavirus concerns spread

gavel
Drugmakers including Mallinckrodt could push aggressively for a settlement during the New York trial's delay. (Pixabay)

With thousands of opioid lawsuits waiting in the wings, several major drugmakers have been prepping their defenses for a precursor trial slated to begin next week in New York. Now, with the novel coronavirus continuing its spread, those companies face a delay on that trial—which, for them, might be a good thing. 

A major New York bellwether opioid trial has been indefinitely postponed "out of an abundance of caution" due to the ongoing outbreak of COVID-19, New York Attorney General Letitia James' office said in a release Tuesday.

The defendants in the New York trial include major players Johnson & Johnson, Allergan, Teva, Purdue, Endo and Mallinckrodt as well as a range of manufacturers, distributors and pharmacies. 

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.

The decision from Vito C. Caruso, deputy chief administrative judge for courts outside New York City, comes only a week after the court swatted away a defendant request for interim stay, officially slating the trial to begin next week.

James' office said the court would reconvene April 14 "to determine next steps and set a more concrete schedule for trial."

RELATED: Mallinckrodt floats $1.6B opioid deal, bankruptcy for specialty generics unit